Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence

Area of Science:

• Dermatology
• Pediatrics
• Immunology

Background:

• Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition in children, significantly impacting families.
• Topical corticosteroids have historically been the primary treatment for childhood AD.
• Topical calcineurin inhibitors (TCIs), including tacrolimus and pimecrolimus, offer alternative therapeutic options.

Purpose of the Study:

• To evaluate the efficacy and safety of TCIs in pediatric atopic dermatitis management.
• To compare TCIs with placebo and topical corticosteroids.
• To assess the long-term safety profile of TCIs in children with AD.

Main Methods:

• Systematic review of clinical trials involving TCIs for pediatric AD.
• Analysis of studies comparing TCIs to placebo and topical corticosteroids.
• Evaluation of safety data from short-term and extended-use trials.

Main Results:

• TCIs demonstrate effectiveness and safety for both continuous short-term and non-continuous long-term (up to 4 years) use in pediatric AD.
• Clinical trials confirm the efficacy of tacrolimus and pimecrolimus compared to placebo and topical corticosteroids.
• Limited data exists on the long-term safety of TCIs due to their relatively recent clinical availability.

Conclusions:

• TCIs represent a valuable therapeutic option for managing pediatric atopic dermatitis.
• Further long-term safety studies are necessary to fully understand the implications of TCIs use in children.
• The established efficacy and safety profile support the use of TCIs in appropriate pediatric AD cases.